Cumberland Pharmaceuticals Inc. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
Cumberland Pharmaceuticals Inc. (CPIX) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$3.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-07
- Cumberland Pharmaceuticals Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$3.10M.
- Cumberland Pharmaceuticals Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-06-30 was -$3.00M.
- Cumberland Pharmaceuticals Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2022-12-31 was -$2.46M.
- Cumberland Pharmaceuticals Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2022-09-30 was -$423.23K.
- Cumberland Pharmaceuticals Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2025 was -$2.86M.
- Cumberland Pharmaceuticals Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2024 was -$6.44M.
- Cumberland Pharmaceuticals Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2023 was -$6.33M.
- Cumberland Pharmaceuticals Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2022 was -$5.65M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$3.10M 10-Q · filed 2026-08-07 | -$5.96M 10-Q · filed 2026-08-07 | ||||
| 2025-12-31 | -$2.86M 10-K · filed 2026-03-09 | |||||
| 2025-06-30 | -$3.00M 10-Q · filed 2026-08-07 | -$5.61M 10-Q · filed 2026-08-07 | ||||
| 2024-12-31 | -$6.44M 10-K · filed 2026-03-09 | |||||
| 2023-12-31 | -$6.33M 10-K · filed 2025-03-07 | |||||
| 2022-12-31 | -$2.46M 10-K · filed 2023-03-13 | -$2.88M derived: sum of 2 quarters · filed 2023-03-13 | -$4.25M derived: sum of 3 quarters · filed 2023-03-13 | -$5.65M 10-K · filed 2023-03-13 | ||
| 2022-09-30 | -$423.23K 10-K · filed 2023-03-13 | -$1.79M derived: sum of 2 quarters · filed 2023-03-13 | -$3.19M 10-Q · filed 2022-11-14 | -$7.58M derived: sum of 4 quarters · filed 2023-03-13 | ||
| 2022-06-30 | -$1.36M 10-K · filed 2023-03-13 | -$2.77M 10-Q · filed 2022-08-12 | -$7.15M derived: sum of 3 quarters · filed 2023-03-13 | -$8.74M derived: sum of 4 quarters · filed 2023-03-13 | ||
| 2022-03-31 | -$1.40M 10-K · filed 2023-03-13 | -$5.79M derived: sum of 2 quarters · filed 2023-03-13 | -$7.37M derived: sum of 3 quarters · filed 2023-03-13 | -$6.65M derived: sum of 4 quarters · filed 2023-03-13 | ||
| 2021-12-31 | -$4.39M 10-K · filed 2023-03-13 | -$5.97M derived: sum of 2 quarters · filed 2023-03-13 | -$5.25M derived: sum of 3 quarters · filed 2023-03-13 | -$5.60M 10-K · filed 2023-03-13 | ||
| 2021-09-30 | -$1.58M 10-K · filed 2023-03-13 | -$858.80K derived: sum of 2 quarters · filed 2023-03-13 | -$1.21M 10-Q · filed 2022-11-14 | -$3.00M derived: sum of 4 quarters · filed 2023-03-13 | ||
| 2021-06-30 | $724.68K 10-K · filed 2023-03-13 | $373.94K 10-Q · filed 2022-08-12 | -$1.41M derived: sum of 3 quarters · filed 2023-03-13 | -$2.69M derived: sum of 4 quarters · filed 2023-03-13 | ||
| 2021-03-31 | -$350.75K 10-K · filed 2023-03-13 | -$2.14M derived: sum of 2 quarters · filed 2023-03-13 | -$3.41M derived: sum of 3 quarters · filed 2023-03-13 | -$5.09M derived: sum of 4 quarters · filed 2023-03-13 | ||
| 2020-12-31 | -$1.79M 10-K · filed 2022-03-11 | -$3.06M derived: sum of 2 quarters · filed 2022-03-11 | -$4.74M derived: sum of 3 quarters · filed 2022-03-11 | -$6.63M 10-K · filed 2022-03-11 | ||
| 2020-09-30 | -$1.28M 10-K · filed 2022-03-11 | -$2.95M derived: sum of 2 quarters · filed 2022-03-11 | -$4.84M 10-Q · filed 2021-11-12 | -$4.84M 10-Q · filed 2020-11-13 | -$8.21M derived: sum of 4 quarters · filed 2022-03-11 | |
| 2020-06-30 | -$1.68M 10-K · filed 2022-03-11 | -$3.56M 10-Q · filed 2021-08-13 | -$6.93M derived: sum of 3 quarters · filed 2022-03-11 | -$10.25M derived: sum of 4 quarters · filed 2022-03-11 | ||
| 2020-03-31 | -$1.88M 10-K · filed 2022-03-11 | -$5.25M derived: sum of 2 quarters · filed 2022-03-11 | -$8.57M derived: sum of 3 quarters · filed 2022-03-11 | -$9.91M derived: sum of 4 quarters · filed 2022-03-11 | ||
| 2019-12-31 | -$3.37M 10-K · filed 2021-03-12 | -$3.37M 8-K · filed 2020-12-10 | -$6.69M derived: sum of 2 quarters · filed 2021-03-12 | -$8.02M derived: sum of 3 quarters · filed 2021-03-12 | -$9.21M 10-K · filed 2022-03-11 | |
| 2019-09-30 | -$3.32M 10-K · filed 2021-03-12 | -$4.65M derived: sum of 2 quarters · filed 2021-03-12 | -$5.84M 10-Q · filed 2020-11-13 | -$9.11M derived: sum of 4 quarters · filed 2021-03-12 | ||
| 2019-06-30 | -$1.34M 10-K · filed 2021-03-12 | -$2.53M 10-Q · filed 2020-08-14 | -$5.79M derived: sum of 3 quarters · filed 2021-03-12 | -$8.30M derived: sum of 4 quarters · filed 2021-03-12 | ||
| 2019-03-31 | -$1.19M 10-K · filed 2021-03-12 | -$1.19M 10-Q · filed 2020-05-22 | -$4.46M derived: sum of 2 quarters · filed 2021-03-12 | -$6.96M derived: sum of 3 quarters · filed 2021-03-12 | -$8.75M derived: sum of 4 quarters · filed 2021-03-12 | |
| 2018-12-31 | -$3.27M 8-K · filed 2020-12-10 | -$5.77M derived: sum of 2 quarters · filed 2020-12-10 | -$7.57M derived: sum of 3 quarters · filed 2020-12-10 | -$10.82M 10-K · filed 2021-03-12 | ||
| 2018-09-30 | -$2.50M 8-K · filed 2020-12-10 | -$4.30M derived: sum of 2 quarters · filed 2020-12-10 | -$7.55M derived: sum of 3 quarters · filed 2020-12-10 | |||
| 2018-06-30 | -$1.80M 8-K · filed 2020-12-10 | -$5.05M derived: sum of 2 quarters · filed 2020-12-10 | ||||
| 2018-03-31 | -$3.26M 8-K · filed 2020-12-10 | |||||
| 2017-12-31 | -$12.85M 8-K · filed 2020-12-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |